Symbol="RLMD"
AssetType="Common Stock"
Name="Relmada Therapeutics Inc"
Description="Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to treat central nervous system (CNS) diseases and other disorders in the United States. The company is headquartered in New York, New York."
CIK="1553643"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="546 FIFTH AVENUE, 14TH FLOOR, NEW YORK, NY, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="76452000"
EBITDA="-161247824"
PERatio="None"
PEGRatio="None"
BookValue="4.169"
DividendPerShare="0"
DividendYield="0"
EPS="-4.77"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.523"
ReturnOnEquityTTM="-0.855"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-4.77"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="10.63"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="0.574"
EVToRevenue="-"
EVToEBITDA="0.566"
Beta="0.0821"
num_52WeekHigh="38.68"
num_52WeekLow="1.81"
num_50DayMovingAverage="2.688"
num_200DayMovingAverage="3.563"
SharesOutstanding="30099200"
DividendDate="2019-09-30"
ExDividendDate="None"
symbol="RLMD"
open="2.63"
high="2.72"
low="2.52"
price="2.54"
volume="63705.00"
latest_trading_day="2023-08-04"
previous_close="2.61"
change="-0.07"
change_percent="-2.6820%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="63"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="37"
Volume_recent_avg="191072"
Change_recent_avg="-0.01"
Delta_recent_avg="0.22"
Variance_recent_avg="0.11"
Change_ratio_recent_avg="-0.42"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="37"
Aroon_momentum_negative="63"
image_negative_thumbnail_id_1="1125"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0158.jpeg"
image_negative_thumbnail_id_2="135"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0041.jpeg"
image_neutral_thumbnail_id_1="532"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0067.jpeg"
image_neutral_thumbnail_id_2="541"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0058.jpeg"
image_positive_thumbnail_id_1="694"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0014.jpeg"
image_positive_thumbnail_id_2="634"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0074.jpeg"
image_professor_thumbnail_id_1="1185"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0019.jpeg"
image_professor_thumbnail_id_2="1167"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0001.jpeg"
